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PHARMACOLOGICAL ANTIOXIDANT STRATEGIES AS
THERAPEUTIC INTERVENTIONS FOR COPD
Irfan Rahman
Department of Environmental Medicine, Lung Biology and Disease Program, University of
Rochester Medical Center, Rochester, NY, USA
Abstract
Cigarette/tobacco smoke/biomass fuel-induced oxidative and aldehyde/carbonyl stress are
intimately associated with the progression and exacerbation of chronic obstructive pulmonary
disease (COPD). Therefore, targeting systemic and local oxidative stress with antioxidants/redox
modulating agents, or boosting the endogenous levels of antioxidants are likely to have beneficial
effects in the treatment/management of COPD. Various antioxidant agents, such as thiol
molecules (glutathione and mucolytic drugs, such as N-acetyl-L-cysteine and N-acystelyn,
erdosteine, fudosteine, ergothioneine, and carbocysteine), all have been reported to modulate
various cellular and biochemical aspects of COPD. These antioxidants have been found to
scavenge and detoxify free radicals and oxidants, regulate of glutathione biosynthesis, control
nuclear factor-kappaB (NF-kappaB) activation, and hence inhibiting inflammatory gene
expression. Synthetic molecules, such as specific spin traps like α-phenyl-N-tert-butyl nitrone, a
catalytic antioxidant (ECSOD mimetic), porphyrins (AEOL 10150 and AEOL 10113), and a
superoxide dismutase mimetic M40419, iNOS inhibitors, lipid peroxidation inhibitors/blockers
edaravone, and lazaroids/tirilazad have also been shown to have beneficial effects by inhibiting the
cigarette smoke-induced inflammatory responses and other carbonyl/oxidative stress-induced
cellular alterations. A variety of oxidants, free radicals, and carbonyls/aldehydes are implicated in
the pathogenesis of COPD, it is therefore, possible that therapeutic administration or
supplementation of multiple antioxidants and/or boosting the endogenous levels of antioxidants
will be beneficial in the treatment of COPD. This review discusses various novel pharmacological
approaches adopted to enhance lung antioxidant levels, and various emerging beneficial and/or
prophylactic effects of antioxidant therapeutics in halting or intervening the progression of COPD.
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1. Introduction
A high-oxygen environment with exogenous pollutants/toxicants constantly being inhaled
through the inhaled breath, significantly challenges the lung tissue. Due to its very high
blood supply and large surface area, the lung is highly susceptible to oxidative stress
mediated injury. In addition, the lung epithelium is constantly exposed to oxidants generated
endogenously during metabolic reactions (e.g., from mitochondrial electron transport
activation of phagocytes), as well as to inhaled oxidants in the ambient air, including ozone,
nitrogen dioxide, diesel exhaust, and cigarette smoke.
Generations of reactive oxygen species (ROS), such as superoxide anion (O2•−) and the
hydroxyl radical (•OH) are directly associated with the oxidative modification of proteins,
lipids, carbohydrates and DNA. Oxidative stress causes cell damage, cell necrosis,
apoptosis, autophagy, remodeling of extracellular matrix and blood vessels, endothelial
dysfunction, inactivation of antiproteases, premature cellular senescence, elevated mucus
secretion, steroid resistance, unfolded protein response, cell proliferation, epigenetic
changes, autoimmunity, and skeletal muscle dysfunction. Furthermore, these oxidants also
influence inflammatory responses in the lungs through activation of transcription factor
nuclear factor kappaB (NF-κB), mitogen-activated protein kinases (MAPK) signal
transduction pathways, chromatin remodeling, and transcription of proinflammatory
mediator genes [1–5]. These processes are intricately associated with the progression of
chronic obstructive pulmonary disease (COPD) [3–8]. Hence, in light of oxidative burden
and its consequences in pathogenesis of COPD, this review is focused on various
antioxidant strategies based on various pharmacological, chemical and functional aspects of
thiols, spin traps, lipid peroxidation and protein carbonylation, and redox sensor inhibitors,
enzyme mimetics, synthetic antioxidants, and redox sensors (Table 1).
2. COPD causes and pathogenesis
COPD is a major and increasing global health problem and is the fourth most common cause
of death in the developed countries. It is a disabling condition associated with progressive
breathlessness with slow decline in lung function. COPD will account for over six million
deaths per year and is predicted to increase from the sixth to the third leading cause of death
by 2020 worldwide. It is the disease associated with oxidative stress and inflammaging
(inflammation and accelerated decline in lung function) when body’s antioxidant defense
gradually weakens. Patients with COPD experience a poorer quality of life, suffer from
comorbidities associated with cardiovascular, muscular (skeletal) and neurological
problems. These comorbidities are associated with increased oxidative stress.
Cigarette smoke is the major risk factor for the development of COPD. Cigarette smoke
contains an estimated 1015–1017 oxidants/free radicals and ~4700 different chemical
compounds, including reactive aldehydes and quinones, per puff [9–11]. Other noxious
environmental gases/particles such as aldehydes/carbonyls, NO2, SO2, and particulate
matters, as well as exposure to second hand tobacco smoke, and smoke derived from
burning of biomass fuel can also cause oxidative stress and trigger inflammatory responses
in the lungs of a susceptible individual.
COPD can be classified into four classes of severity based on lung function [GOLD
Guidelines] [1–2, 4–6]. Emphysema, chronic bronchitis with airway obstruction, and small
airways disease are the distinct phenotypes of COPD, but most patients show a combination
of different overlapping phenotypes. Emphysema is characterized by destruction of the
alveolar septa, loss of elastic recoil, airspace enlargement, and hence loss of gas diffusion
capacity. Chronic bronchitis affects the larger airways by airway inflammation (recruitment
of neutrophils, macrophages, and other immune-inflammatory cells), goblet cell hyperplasia
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and mucus hypersecretion. Apart from decline of lung function, COPD patients experience
chronic sputum production (mucus hypersecretion), coughing, and often dyspnoea. Small
airways disease mainly affects the bronchioles featuring airway inflammation and
metaplasia of Clara cells. The pathogenesis of COPD involves several processes, such as
oxidative stress, pulmonary, and systemic inflammation, protease/antiprotease imbalance,
breakdown in immunity (autoantibody production), apoptosis, autophagy, vascular and
extracellular matrix remodeling, impaired tissue repair, alteration of cell proliferation, and
cellular senescence/premature aging. All of these processes are implicitly associated with
systemic and lung oxidative stress [2] (Fig.1).
3. Cigarette smoke and oxidants
ROS are virtually produced by all of the cells as a result of metabolism within the
mitochondria and additionally by inflammatory cells and phagocytes, such as macrophages
and neutrophils, as well as during the immuno-inflammatory response against a pathogen.
NADPH (nicotinamide adenine dinucleotide phosphate) oxidase enzyme complex, present
in phagocytes and epithelial cells, xanthine/xanthine oxidase system, myeloperoxidase, and
the heme peroxidases are the main generators of ROS and have been found to be elevated in
COPD patients [12–14].
Similarly, nitric oxide synthase generates reactive nitrogen species (RNS) in the form of
nitric oxide (NO). NO can combine with O2•− to form a more damaging peroxynitrite anion
(ONOO−) leading to formation of nitrotyrosine. It has now been reported that the
physiological action of an oxidant depends on the source of its generation. For example,
oxidants derived from NADPH oxidase mainly participate in cell signaling, while those
produced excessively by mitochondria induce cell damage/death [15].
Production of ROS by phagocytes can be enhanced by oxidants present in cigarette smoke
leading to the release of inflammatory mediators. Some of these mediators are chemotactic
in nature and lead to the recruitment of neutrophils and other inflammatory cells into the
lungs. Smokers and patients with COPD have greater migration of macrophages and
neutrophils into their lungs as compared to non-smokers. These cells can generate ROS via
the activation of NADPH oxidase complex system, leading to further augmentation of
oxidative stress in lungs of smokers and patients with COPD [2–5].
3.1. Cigarette/tobacco smoke as a source of oxidants and carbonyls
Cigarette smoke contains more than 1015–17 oxidant/free radical molecules per puff and over
4,700 highly reactive chemical compounds including aldehydes/carbonyls [9], this adds to
the oxidant burden in current smokers. The gas phase of cigarette smoke contains relatively
short-lived O2•− and NO, which immediately react to form the highly reactive and toxic
peroxynitrite ONOO−. A very high diffusion coefficient of ONOO− allows it to diffuse over
a greater distance, thus causing more tissue damage in lung interstitium/microenvironment
at the site of generation. The tar phase of cigarette smoke contains organic radicals, such as
long-lived semiquinone and quinone radicals, which can rapidly react with molecular
oxygen in a redox dependent manner leading to generation of various ROS, such as
O2•−, •OH, and H2O2 [10–11]. The aqueous phase of cigarette smoke condensate (simulated
as bronchoalveolar fluids of smokers) may undergo redox recycling for a considerable
period of time in the epithelial lining fluid (ELF) of smokers [10]. The tar phase is also an
effective metal chelator, wherein iron is chelated to produce tar-semiquinone and tar-Fe2+,
which can generate H2O2 continuously [10].
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3.2. Cigarette smoke, lipid peroxidation and protein carbonylation
Systemic and lung formation of protein carbonyls (aldehyde protein adducts) in response to
cigarette smoke-derived lipid peroxides/carbonyls (aldehydes) have been implicated in the
pathogenesis of COPD. The levels of lipid peroxidation products, such as 8-isoprostane/F2-
isoprostanes are increased in smokers and in patients with COPD [16–17]. Furthermore, the
levels of these lipid peroxidation products have been correlated with airway obstruction
[16]. 4-hydroxy-2-nonenal (4-HNE) is a specific, highly reactive, and diffusible end-product
of lipid peroxidation. 4-HNE forms adducts with cysteine, lysine and histidine residues of
proteins which are referred as protein carbonyls. Increased 4-HNE-modified protein levels
(protein carbonyls) are present in airway and alveolar epithelial cells and endothelial cells,
and in neutrophils in smokers with airway obstruction compared to subjects without airway
obstruction [17]. The increased level of 4-HNE adducts was inversely correlated with lung
function measured as FEV1, suggesting a role for 4-HNE in the pathogenesis of COPD.
Also, α,β-unsaturated aldehydes (4-HNE and acrolein) contained in cigarette smoke impose
oxidative stress and elicit IL-8 release in pulmonary cells through MAPK activation [18].
3.3. Depletion of antioxidants
Systemic antioxidant capacity is decreased in smokers and in patients with COPD, which is
reflected by decreased plasma antioxidants and protein sulfhydryls [19]. This occurs
transiently during smoking and resolves rapidly after smoking cessation. However, low
grade oxidative stress still persists in ex-smokers who develop COPD. The depletion of
antioxidant capacity and antioxidants is due to the increased release of ROS from peripheral
blood neutrophils and monocytes implying the role of oxidants in the pathogenesis of
COPD. Several other studies have shown the deficiency of antioxidants in both plasma and
lungs of patients with COPD (reviewed in [2, 4–5, 20]). It has also been recently reported
that antioxidants, such as uric acid, glutathione (GSH), vitamin E, and ascorbate are
decreased in smokers, and was associated with the severity of COPD exacerbation [21].
Cigarette smoke irreversibly modifies GSH levels to GSH-conjugates in airway epithelial
cells and epithelial lining fluids leading to antioxidants deficiency and injurious lung
response [3–6, 20]. Cigarette smoking is shown to block the protective expression of Nrf2/
antioxidant response element (ARE) pathway in peripheral mononuclear cells of young
heavy smokers favoring inflammation [22].
4. Therapeutic strategies for COPD
Tissue injury and inflammation due to ROS are common to many disease pathologies
including COPD and this similarity provides a unique antioxidants therapeutic opportunity
wherein numerous lung diseases may be gradually treated by an agent that can suppress
either the generation of ROS or can neutralize such species or both. Perhaps this might be
true at the onset of the disease progression and pathogenesis for antioxidants to be
considered as pre-emptying agents. Nevertheless, overwhelming evidence suggest that
oxidative/carbonyl stress is implicitly involved with the pathogenesis of COPD. A rationale
approach for the treatment of COPD would, therefore, be to consider antioxidant
intervention, not only to neutralize the excessive oxidative stress, inhibit peroxidation of
lipids, and the subsequent inflammatory response, but also to identify the source of oxidants
and overwhelm their generation. This can be achieved by two approaches, either by
increasing the endogenous antioxidant enzyme defenses or by enhancing the non-enzymatic
defenses through dietary or pharmacological means. Several small-molecular weight
antioxidant compounds that target oxidant signaling, or quench cigarette smoke-derived
oxidants and reactive aldehydes are currently being tested clinically and pre-clinically [4,
20, 23]. Antioxidant agents, such as thiol compounds/donors and analogs (GSH and
mucolytic drugs, such as N-acetyl-L-cysteine (NAC), nacystelyn (NAL), erdosteine,
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fudosteine, and carbocysteine lysine salt), and ergothioneine have all been reported to
scavenge/detoxify free radicals/oxidants, increase intracellular thiol levels, control NF-κB
activation, and consequently inhibit inflammatory gene expression. Other compounds
include dietary antioxidants, superoxide dismutase (SOD) mimetics, and synthetic redox
modulating agents. Several strategies either to increase the expression/activity of the
antioxidant enzymes or to mimic their function by enzyme mimetics have been developed.
In this review, the beneficial and/or prophylactic effects of a variety of antioxidants are
discussed. These antioxidant molecules may have the potential to be used as
pharmacological therapeutic agents in the management and treatment of COPD. The pros
and cons for targeting oxidative stress by antioxidants in treatment of COPD are given in
Table 2.
Dietary antioxidants, such as antioxidant vitamins and carotenoids (vitamin C, tocopherol,
β-carotene), and natural products-containing dietary polyphenols/flavanoids, and other
active compounds (curcumin, resveratrol, green tea-catechins, quercetin), lycopene, acai,
ginkgo biloba, polyunsaturated fatty acids/omega-3 fatty acid, tocotrienols, alpha-lipoic
acid, and apocynin are also important in management of oxidative stress imposed by
cigarette smoke in smokers and patients with COPD [4–5]. However, the beneficial effects
of these dietary products are not part of this review, but have been discussed elsewhere [4–
5].
5. Antioxidant enzyme mimetics and spin traps
Antioxidants, such as SOD, catalase, and glutathione peroxidase play an important role in
the neutralization of free radicals in the cells. However, their expression and activities are
altered in the lungs of smokers and patients with COPD [1–6]. Alterations in antioxidant
enzyme activity can be overcome by small compounds possessing catalytic properties.
These compounds can mimic the activity of a larger enzyme-based molecule, which are
known as enzyme mimetics.
5.1. SOD mimetics
Three classes of manganese (Mn)-containing SOD mimetics have been developed. The first
class includes several macrocyclic Mn(II)-pentaazamacrocyclic ligands, such as M40401,
M40403, and M40419 [24–25]. Mn(III)-metaloporphyrins, such as AEOL-10113 and
AEOL-10150 form the second class of SOD mimetics [26–27], and Mn(III)-salen
complexes forms the third class. Since the ‘Salens’ are also reported to have catalase-like
activity, they can therefore neutralize H2O2 in the cells. In addition, Mn(III)-salen
complexes can also decompose ONOO− [28]. Therefore, Salens appear to have a non-
selective nature of action, a property attributed to the multivalent state in which they can
exist. In an animal model of lung disease, M40419 has been shown to significantly decrease
the markers of oxidative stress in the lungs, and to block the development of emphysema
[24]. Since studies with recombinant SOD treatment has shown to prevent neutrophil influx
into the lungs and decrease IL-8 release induced by cigarette smoking [29], it is therefore,
possible that these compounds, which possess antioxidant enzyme properties may be used as
novel antioxidant/anti-inflammatory drugs in COPD. In an ovalbumin challenged model of
airway inflammation, AEOL10113 was found to inhibit both airway inflammation and
airway hyperreactivity [26]. In another study in rats, AEOL10150 was shown to inhibit
cigarette smoke-induced lung inflammation and decreased lipid peroxidation as well as
generation of ONOO− [27].
The metalloporphyrin-based catalytic antioxidant, MnTE-2-PyP (Manganese (III) Meso-
Tetrakis-(NMethlypyridinium-2-yl) porphyrin) has broad antioxidant properties, and has
been reported to scavenge superoxide, lipid peroxides, ONOO−, and H2O2 [30–32].
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Inflammation and injury induced by a wide variety of factors, such as radiation, bleomycin,
or lipopolysaccharide exposure is also decreased by MnTE-2-PyP [33–34]. MnTE-2-PyP
also reduces NF-κB signaling by modulating the redox environment of the cell [33]. The
ability of MnTE-2-PyP to affect such a wide variety of different disease states has been
attributed to its ability to alter inflammatory redox cell signaling [35].
Another SOD/catalase mimetic EUK-189 when administered in rats subjected to heat stress,
improved hepatic functions, redox status, decreased oxidative injury, and DNA binding
activity of redox response transcription factor NF-κB [36]. EUK-189 also preserved the
redox potential in aged heat-stressed rats by maintaining GSH/GSSG ratios to normal
control levels. Furthermore, EUK-189 also increased the expression of stress-responsive
protein, heat shock protein 72 (HSP70) in rats subjected to heat stress [37]. Overexpression
of SOD1 attenuates cigarette smoke- and elastase-mediated emphysema in mice [38].
Interestingly, a recent observation that sustained lung activity particularly in pulmonary
vascular bed of a novel chimeric protein SOD2/3 can be achieved by intratracheal
administration in rats [39]. Therefore, these compounds appear to have potential for
therapeutic use in COPD.
The third type of SOD, extracellular superoxide dismutase (ECSOD or SOD3) is highly
expressed in lungs and vessels [40] and is located in the extracellular matrix (ECM), the
junctions of airway epithelial cells, the surface of airway smooth muscle, and the lining of
blood vessels of the lung. Since SOD3 scavenges O2•− , it may therefore, play an important
role in oxidative lung damage and injury. It has been reported tha2- , it may therefore, play
an important role in oxidative lung damage and injury. It has been reported that acute loss of
SOD3 in adult mice causes death, whereas overexpression of SOD3 in animals exposed to
hyperoxia reduces mortality, suggesting an essential role of SOD3 for survival against the
lethal effect of hyperoxia [41–42]. In cigarette smoke/elastase induced emphysema mouse
model, SOD3 was shown to protect the lung against pulmonary emphysema, which was
attributed to the reduction of oxidative ECM fragmentation and oxidative posttranslational
modifications of elastin fragments (leading to autoantibody production) in the lung [43].
Similarly, a recent study showed that SOD3 down modulated CS-induced oxidative stress in
mouse macrophages [44]. Hence, SOD3 may be more effective than other SODs in
management of emphysema or more severe COPD phenotype.
Smoking and COPD were also found to increase sputum levels of extracellular superoxide
dismutase due to adaptive response [45]. Polymorphisms in the SOD3 gene were associated
with emphysema, but not COPD susceptibility, highlighting the importance of phenotype
definition in COPD genetic studies [46–47]. Furthermore, administration of SOD mimetic
significantly attenuated the elastase-induced emphysema in both wild-type and SOD3
knockout mice, and the level/activity of SOD3 was decreased in the emphysematous mouse
lung. As mentioned above, SOD3 was also reported to protect against oxidative
fragmentation of ECM, such as heparin sulfate and elastin, thereby attenuating lung
inflammatory response and emphysema [43]. Therefore, the development of
pharmacological mimetics to replenish/augment SOD3 specifically in the lung (matrix) may
have a therapeutic potential in the intervention of COPD/emphysema. Furthermore, SOD3
therapy can be combined with other therapeutic approaches in management of COPD.
5.2. Glutathione peroxidase (GPx) mimetic
Ebselen, a selenium-based organic complex, has been found to mimic the activity of
glutathione peroxidase (GPx). Since ebselen can also increase the efficiency of GSH, it can
thus be used as therapy against oxidative stress and inflammation. Ebselen possesses strong
antioxidant activity and has been reported to have strong neutralizing effect against
peroxynitrite radical [48]. In human leukocytes exposed to peroxynitrite, ebselen was found
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to inhibit the activation of NF-κB/AP-1 and expression of pro-inflammatory genes
expression. In vivo activity of ebselen has been demonstrated by virtue of its ability to
prevent LPS-induced airway inflammation [49–50]. However, its protective effect against
cigarette smoke induced lung inflammation is yet to be reported. BXT-51072 and
BXT-51077, which are low molecular weight, orally active organoselenium GPx mimetic
have shown to possess the peroxide neutralizing capabilities and regulate inflammation by
preventing the activation of inflammatory mediators [51]. The mechanism underlying these
protective effects is thought to be via inhibition of transcription of the inflammatory
mediators.
5.3. Peroxynitrite decomposition catalysts
Peroxynitrite decomposition catalysts, unlike other enzyme mimetics, possess catalytic
activity against peroxynitrite. They are iron containing porphyrin complexes and are similar
in structure to AEOL10150 and AEOL10113. In neonatal rat intestinal ischemic-reperfusion
model, administration of FeTMPyP, a peroxynitrite decomposition catalyst, provided limited
protection by reducing P-selectin expression, systemic NO production, neutrophil infiltration
in ileum and lipid peroxidation in both lungs and ileum; and preserved intestinal antioxidant
capacity [52]. Another peroxynitrite decomposition catalyst, FP15, decreased ischemic
injury in rats and improved cardiac function and survival of mice in a chronic model of
doxorubicin-induced cardiotoxicity [53]. The efficacy of peroxynitrite decomposition
catalysts has been reported in vivo in various animal models of disease associated with
peroxynitrite generation [54]. However, it remains to be seen whether or not this class of
antioxidants is also effective in a smoking model for COPD associated with high levels of
peroxynitrite generation.
5.4. Spin traps
Spin traps are chemical agents, which can quench free radicals and are as such used
experimentally for studying reactions involving free radicals. On trapping free radicals, spin
traps form a stable end product suitable for measurement. Most spin traps have a nitrone- or
nitroxide-nucleus and are derivatives of these moieties. Although spin traps have been
extensively used for in vitro studies, their therapeutic in vivo effects have also been
investigated in inflammation using α-phenyl-N-tert-butyl nitrone [55]. One of the
difficulties of studying with earlier spin traps was their extremely small half lives and their
generation of dangerous •OH on decay. This disadvantage has however, been overcome by
introduction of electron withdrawing moieties around the core pyrroline ring [56]. Spin traps
containing nitrone- core have been shown to possess strong antioxidant properties, and their
therapeutic effects have been investigated in Alzheimer’s and Parkinson’s diseases [57].
Isoindole-based nitrones [58] and azulenyl-based nitrones [59] are already in vogue and one
such agent STANZ has been reported to have strong antioxidant properties and can inhibit
lipid peroxidation in vitro. A phenyl-based nitrone spin trap NXY-059 has been tested in
acute ischemic stroke. These compounds have also been shown to impart therapeutic
benefits in a number of animal models of lung disease. Recent studies have suggested that
inhibition of NO generation via iNOS inhibition by various chemical inhibitors [N(6)-(1-
iminoethyl)-L-lysine (L-NIL), G-nitro-L-arginine-methyl ester or L-NAME or using the
knockout mouse model resulted in attenuation of emphysema [60–61]. This effect may be
due to the removal of NO so that ONOO will not be formed. It is possible that selective
inhibition of iNOS along with supplementation of other antioxidants may provide a strategy
in management of severe COPD. Further investigations are required to develop these
compounds (spin traps and iNOS) for long-term use in cigarette smoke/oxidative stress
mediated chronic lung diseases including COPD.
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5.5. Nrf2 activators
Nuclear factor erythroid 2 p45-related factor 2 (Nrf2) is a basic-leucine zipper (b-ZIP)
transcription factor present in the cytoplasm [62]. It plays a pivotal role in cellular defense
against electrophiles and ROS present in cigarette smoke. In response to various factors,
such as oxidative, carbonyl and electrophilic stresses, Nrf2 detaches from its cytosolic
inhibitor, Kelch-like ECH-associated protein 1 (Keap1), and translocates into the nucleus.
Upon entering in the nucleus, Nrf2 binds to ARE of target genes along with other binding
factors and cofactors leading to an induction of stress response genes [63–65]. Most of the
antioxidants and phase II cytoprotective genes, such as heme oxygenase-1 (HO-1),
NAD(P)H/quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase, glutamyl cysteine
synthase, glutathione peroxidase, and several members of the glutathione S-transferase
family are regulated by Nrf2 [63, 66–67].
Studies have also shown increased susceptibility of Nrf2 null mice to cigarette smoke-
induced emphysema compared with wild-type mice [68–69], suggesting the protective role
of Nrf2. Furthermore, Nrf2 appears to protect against pulmonary hyperoxia/bleomycin
injury and ovalbumin challenge in mice, presumably by upregulating the transcription of
lung antioxidant defense enzymes. It has been shown that reduction of Nrf2 protein levels in
pulmonary macrophages and in lungs of patients with COPD occurs via loss of Nrf2 positive
regulator DJ-1 and posttranslational modifications of the Keap1–Bach1 equilibrium [70–72].
There is a possibility that polymorphisms in the promoter region of Nrf2 gene may affect the
phenotype in COPD. The levels of Nrf2 protein are decreased in lungs of patients with
COPD, and this decrease was associated with reduction/oxidative posttranslational
modifications and degradation of histone deacetylase 2 (HDAC2) [73–74].
HDAC2 is known to be post-translationally modified by carbonylation and S-nitrosylation
on cysteine residues [75–78]. S-nitrosylation of HDAC2 is known to occur at Cys 262 and
Cys 274 which does not affect its deacetylase activity [79]. A recent study has shown that in
alveolar macrophages obtained from patients with COPD, S-nitrosylation of HDAC2 at
Cys-262 and Cys-274 is increased, and this modification abolishes its GR-transrepression
activity, and renders corticosteroid insensitive for its efficacy [80]. Furthermore, activation
of Nrf2 by sulforaphane denitrosylates HDAC2, and subsequently restores dexamethasone
sensitivity in alveolar macrophages. It is also known that HDACs inactivation by oxidative/
carbonyl stress may antagonize deacetylase activity [81]. Aldehydes, such as 4-HNE and
acrolein alkylate (carbonylate) HDAC2 by covalent modification at two conserved cysteine
residues, corresponding to Cys(261) and Cys(273) [81]. Hence, it remains to be seen
whether S-nitrosylation and thiol alkylation which occurs on these cysteine residues would
also be reversed by Nrf2 activation, though oxidative/nitrosative posttranslational of
HDAC2 is subject to ubiquitination and proteosomal degradation [77]. Furthermore, Nrf2
and HDAC2 both are carbonylated in response to CS and in patients with COPD. These dual
modifications on each molecule (cysteine residues) may cause specific steric hindrance and
post-translational modifications can lead to proteosomal degradation. Nevertheless, it may
be possible to reverse the carbonylation and S-nitrosylation of HDAC2 by pharmacological
means (via activation of thioredoxin reductase and carbonyl/aldehyde reductases) so that
they can function effectively in early stages of COPD and overcome steroid resistance.
Compounds which are potent activators of Nrf2, may buffer the antioxidant potential in the
lung against cigarette smoke, particularly in patients with COPD, can thus be developed for
their therapeutic application. Alternatively, novel compounds which are potent activators of
Nrf2 or which stabilize Keap1/DJ-1/Maf proteins can be developed. Therapeutically, it has
been shown that activating Nrf2 with the compound 1[2-Cyano-3,12-dioxooleana-1,9(11)-
dien-28-oyl]imidazole (CDDO)-imidazolide can reduce CS- and LPS-induced inflammation
providing a novel therapeutic strategy for COPD [65, 82]. Such compounds will augment
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the antioxidant potential in the lung against cigarette smoke, particularly in patients with
COPD. Furthermore, it may be possible to combine the strategy of Nrf2 activators with
other currently available therapeutic options (e.g. phosphodiesterase 4 inhibitors,
bronchodilators, and steroids) in management of COPD. However, one has to keep in mind
whether there is a polymorphisms in the promoter region of Nrf2 gene in susceptible
smokers and patients with COPD.
Various small molecule activators of Nrf2 signaling are currently being investigated for their
anticancer and anti-inflammatory properties (both lung cancer and COPD are associated to
cigarette/tobacco smoke exposure). A wide variety of dietary and synthetic compounds that
function as potent inducers of ARE-regulated gene expression have been shown to exert
chemopreventive activities, e.g., various dietary and synthetic compounds, such as
sulforaphane [82], dithiolethione [83], curcumin and caffeic acid phenethyl ester (CAPE)
[84] have been reported as potent inducers of ARE regulated genes.
Chalcones or chalconoids (1,3-diphenyl-2-propen-1-ones) and Michael acceptors are
important groups of naturally occurring compounds of antioxidant and chemoprotective
agents [85]. Chalcones have been found to have relevant physiological properties, due to
their ability to bind to proteins related to cell apoptosis and proliferation [86]. Recently, it
has been reported that chalcones can impart anti-inflammatory effects due to the inhibition
of the NF-κB pathway [87–88]. Furthermore, chalcones have also been reported to activate
Nrf2/ARE pathway, thus inducing phase II detoxifying enzyme expression [89]. Currently,
various derivatives of chalcones are being developed for improving the anti-inflammatory
and anti-cancer properties of chalcones, which may find potential therapeutic role in COPD
[62].
6. Redox sensors: Enzymatic and non-enzymatic
The intracellular redox state is a dynamic system and is constantly influenced by the energy
status of the cell. Various external and internal factors can alter the redox state of the cell.
The most common redox sensors of the cell include the NADP/NADPH, NAD+/NADH, and
glutathione systems (GSH/GSSG). Since the relative concentrations of the reduced versus
oxidized components of these redox couples determine the overall redox state of the cell, the
effect of any external oxidative stress is detected by these redox sensors. While GSH is the
most abundant cytosolic thiol redox sensor, the NADP/NADPH system acts as a buffer
against mitochondrial redox shifts. In addition, NADP/NADPH is associated as a cofactor
with several enzymatic reactions and with lipid metabolism.
6.1. Thioredoxin
Thioredoxin (Trx) and redox effector factor-1 (Ref-1) belong to oxidoreductase family of
redox sensors. During oxidative stress, Trx, which is bound to proteins, such as
hepatopoietin [90] and the apoptosis signal regulating kinase (ASK-1) [91], as heterodimeric
complexes are released from these complexes liberating the proteins [90]. This leads to the
multimerization of ASK-1 and dimerization of hepatopoietin. In the dissociated form, Trx
reduces a key thiol group within cys62 of the p65/NF-κB subunit in the nucleus leading to
transcriptional activation [92]. Concomitantly, the prevailing oxidative stress activates free
ASK-1, leading to the activation of the pro-inflammatory p38MAPK and JNK pathways [3–
5, 20]. The two pathways discussed above are redox sensitive, which is supported by the
observation, wherein inhibition of Trx (may lead to reducing environment in the nucleus)
with MOL-294 (a small molecular weight inhibitor of Trx), blocks activation of both pro-
inflammatory NF-κB and AP-1-dependent transcription. Inhibition of NF-κB activation by
MOL-294, is also accompanied by diminished neutrophil influx and TNF-a production [93].
Similarly, Ref-1, another redox sensor, on inhibition by PNRI-299, leads to the inactivation
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of AP-1 pathway [94]. Furthermore, in vivo administrations of both MOL-294 and
PNRI-299 in a murine ovalbumin challenge model of asthma have been shown to reduce
various clinical parameters [94–95]. On the contrary to above findings, Trx, overexpression
of Trx-1 or treatment of mice with recombinant human Trx attenuates cigarette smoke-
mediated oxidative stress and pulmonary emphysema [96]. This may be due to its direct
intra- or extracellular antioxidant property rather than its nuclear effect. However, this
molecular effect in cigarette smoke-mediated lung damage, inflammatory response, and in
pathogenesis of COPD remains to be investigated.
A family of tri- and tetra-oligopeptides derived from the canonical CxxC motif of the Trx
active site and a modified CxC motif has been recently synthesized [97]. These constitute
the Trx-mimetic compounds, which are N- and C-terminal-blocked peptides that consist of
two cysteine residues that flank the two-amino-acid CxxC motif (CB4 and CB6) or the
single-amino-acid CxC motif (CB3). These Trx-mimetics have been reported to upregulate
various redox sensitive processes in the cell [97]. Thus, upregulation of Trx by various
synthetic small molecules may be an important strategy employed against oxidative stress
and abnormal inflammatory responses occuring in patients with COPD.
6.2. Peroxiredoxins
Peroxiredoxins (Prdx), are members of a superfamily of selenium-independent peroxidases.
Prdx exerts a protective role through peroxidase activity against H2O2, peroxynitrite and
phospholipid hydroperoxides [98–99]. Depending on the number of active Cys residues,
mammalian Prdx falls into typical double-cysteine (Prdx1-Prdx4), atypical double-cysteine
(Prdx5), and single-cysteine (Prdx6) classes. Prdx6 is highly expressed in the lung tissue,
alveolar epithelial type II cells, bronchial Clara cells, and alveolar macrophages [100–101].
Prdx6 protects against oxidative stress–induced lipid peroxidation and apoptosis and
regulate cellular signaling [102]. Therefore, it appears that Prdx6 is an important protective
enzyme that counteracts oxidant stress in the lung. The important protective role of Prdx in
defense against oxidative stress was demonstrated in a study involving PRDX1 gene
knockout mice [103]. In another study, it was hypothesized that targeted disruption of
PRDX6 would lead to enhanced susceptibility to cigarette smoke (CS)-mediated lung
inflammation and/or emphysema in mouse lungs [104]. However, this study revealed that
targeted disruption of Prdx6 did not increase lung inflammation, but was associated with
increased antioxidants, suggesting a critical role of lung Prdx6 and several compensatory
antioxidant mechanisms during acute CS-induced adaptive response. Furthermore, it was
found that the protective effect of Prdx6 was lost in chronic CS exposure leading to
pulmonary emphysema. Prdx acts as a substrate for sulfiredoxins (Nrf2-dependent), another
enzyme important in redox antioxidant pathways. Strategies to increase the expression of
Prdx or pharmacological amplification by small molecules may, therefore, be beneficial in
the treatment of COPD.
6.3. Glutaredoxin
Glutaredoxins (Glrx) are thiol disulfide oxido-reductases, which possess antioxidant and
catalytic functions closely associated with GSH. Glrx1 is a potential redox modulatory
protein regulating the intracellular, as well as extracellular homeostasis of glutathionylated
proteins and GSH in human lung. Glrx1 is implicated in regulation of pro-inflammatory NF-
κB signaling and chromatin modifications [105–106]. In a cross-sectional study, it has been
demonstrated that Glrx1 was mainly expressed in alveolar macrophages, extracellular fluids
and sputum supernatants, and the levels of this enzyme were decreased in COPD patients
[107]. Glrx1 mRNA and protein expression was decreased in alveolar epithelial cells
exposed to CS along with decreased activity and increased protein S-glutathionylation [108].
In the same study, irreversible oxidation and carbonylation of recombinant Glrx1 by CS and
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acrolein was also demonstrated, which was associated with its reduced enzyme activity.
Interestingly, overexpression of Glrx1 attenuated protein S-glutathionylation induced by CS
and increased cell survival [108]. Tracheal epithelial cells of mice deficient in Glrx1 were
found to be more sensitive to CS-induced cell death with corresponding increases in protein
S-glutathionylation [108]. Thus, CS can modulate Glrx1 at both the gene expression level
and also by modifying Glrx1 enzyme activity. A recent study has shown that Glrx1 regulates
cigarette smoke-mediated lung inflammation via S-glutathionylation and differential
modulation of IκB-kinases in mice [105]. Hence, pharmacological intervention or strategies
to increase Glrx1 gene expression and modulate its enzyme activity would have potential in
the regulation of cigarette smoke-mediated lung inflammation in COPD.
7. Small molecule thiol antioxidants
7.1. N-acetyl-L-cysteine (NAC)
NAC is an acetyl derivative of the amino acid, cysteine, and is a strong reducing agent (Fig.
2). NAC has been used as a mucolytic agent and reduces mucus viscosity, thereby
improving muco-cilliary clearance. In the gastrointestinal tract, NAC is deacetylated into
cysteine and also serves as precursor of GSH in the cells. Its ability to reduce disulfide bond
makes it a good reducing agent and also allows it to neutralize oxidant species. Within the
cells, NAC reduces cystine into cysteine, and may thus serve as an important mechanism for
elevation of intracellular GSH in vivo in lungs. Oral NAC attenuates elastase-induced
pulmonary emphysema in rats implicating its possible role in the management of COPD
[109].
Clinical studies regarding the beneficial effects of NAC and other thiols in patients with
COPD has yielded mixed results (Table 3) [110–122]. While a Cochrane systematic review
showed a significant reduction of 0.79 exacerbations per patient per year compared with
placebo, a 29% decrease in number of exacerbations, whereas small-scale trials failed to
demonstrate any clear clinical benefits [113]. However, a few meta-analyses have shown a
small, but significant clinical benefit in patients with COPD [115, 123].
Considering that GSH plays an important role in the control of oxidative/carbonyl stress in
COPD, NAC has mainly been used, although with varying success, to enhance lung GSH in
patients with COPD [116]. A randomized, double-blind, placebo controlled phase II trial,
with a 6-month oral dose of 600 mg NAC, twice daily, was found to significantly reduce
various plasma and BAL fluid oxidative biomarkers in smokers [124]. Another study
involving oral administration of NAC (600 mg twice daily for 2 months) was shown to
rapidly reduce oxidant load in the airways of stable COPD patients [120], and was
associated with a reduction in bronchial mucus hypersecretion and a decline in FEV1, and
COPD exacerbations [114].
NAC has a beneficial effect on systemic oxidative stress as oral administration of NAC was
found to increase the quadriceps endurance time of severe COPD patients [125]. In contrast,
another multicenter study using NAC delivered by metered-dose inhalers in patients with
chronic cough did not show any beneficial effect on well-being, sensation of dyspnea,
cough, or lung function [126]. Although there is a body of evidence suggesting beneficial
effects of NAC in COPD patients, it is not clear whether NAC is used as a mere
maintenance therapy [110]. However, a phase III multicenter trial, Bronchitis Randomized
on NAC Cost-Utility Study (BRONCUS), has supported this notion [127]. Although
BRONCUS study showed no effect on decline in FEV1, a reduction in overinflation and
exacerbation in patients with severe COPD not treated with inhaled glucocorticoids was
observed [111]. In a recent study, using an infection model of A549 alveolar epithelial cells
infected with the influenza virus, NAC was found to inhibit induction of MUC5AC,
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interleukin (IL)-8, IL-6, and TNF-alpha [128]. NAC was also shown to inhibit the
replication of the influenza virus in the same study.
In view of the above, and due to conflicting reports on the beneficial effects of NAC, further
studies are required using NAC at higher doses (1200 or 1800 mg/day, or even higher doses)
or by using other thiol agents with greater bioavailability in order to observe any clinical
benefits on lung function, reduced exacerbation rate, and improved health status/quality of
life. Overall, NAC can be perceived to play a therapeutic role in the management of COPD
due to its ability to increase intracellular GSH, along with its known mucolytic properties.
Therefore, NAC may be more likely to be of benefit in subjects with mucus hypersecretion
and in other COPD phenotypes, which requires further clinical studies regarding NAC as a
therapeutic alternative against COPD and its pulmonary emphysema phenotype.
7.2. N-acystelyn (NAL)
NAL, a lysine salt of NAC, is also a mucolytic and antioxidant (reducing) thiol compound
(Fig 2). While NAC is acidic in solution, NAL has a neutral pH in solution and can be
aerosolized into the lung without significant side effects [129]. In a comparative study
involving NAL and NAC, it was found that both of the compounds enhanced intracellular
GSH in lung alveolar epithelial cells and inhibited the release of H2O2 and O2•– from human
blood-derived polymorphonuclear leukocytes in smokers and patients with COPD [129].
This study also revealed that NAL could inhibit ROS generation by serum-opsonized
zymosan stimulated human polymorphonuclear neutrophils in a fashion similar to NAC.
NAL could also act as an anti-inflammatory agent, as shown in a study where NAL was
shown to inhibit oxidant-mediated IL-8 release in monocytes. Therefore, NAL is an
antioxidant and anti-inflammatory agent, which may have a potential therapeutic benefit for
COPD treatment. Its ability to be aerosolized adds to its therapeutic advantage. For example,
the lung deposition of NAL was shown to be effective, when given via a metered dose
inhaler formulation in healthy subjects [130]. Befitting from its therapeutic advantage, a
clinical trial using NAL for treatment of COPD is needed.
7.3. Procysteine and GSH-esters
Procysteine (L-2-oxothiazolidine-4-carboxylate or cysteine l-2-oxothiazolidine-4-carboxylic
acid) is a cysteine-relieving compound that increases the intracellular cysteine levels, and
has greater bioavailability than NAC. This thiol compound is well-tolerated and has been
shown to increase mitochondrial levels of GSH in alveolar type II cells [131]. A recent study
by Hodge et al showed that cigarette smoke-induced changes to alveolar macrophage
phenotype activated M1 (proinflammatory; regulation of antigen presentation) or
alternatively activated M2 (poor antigen presentation; improved efferocytosis) markers and
function (efferocytosis and proinflammatory cytokine production) are improved by
treatment with procysteine in mouse lung. It is concluded that the increased efferocytosis
and availability of GSH in response to procysteine may be useful as adjunct therapy for
improving macrophage function in COPD and in susceptible smokers [132].
Glutathione esters, particularly GSH monoethyl esters, can increase the GSH levels of the
cells by cleavage of ester bond (an ethyl group esterified to glycine). GSH esters have been
shown to increase GSH levels in the lungs of rats and in vitro in epithelial cells; however,
this compound can be cytotoxic, and variation in the uptake levels of GSH has been shown
in various cellular models [133]. Furthermore, it may be cautious to note that therapeutic
strategies involving GSH or its analogs or thiol compounds must be carefully designed
keeping in mind the species barrier, bioavailability, half-life of the analogs, and generation
of toxic byproducts by the analogues, as well as interference with metabolic and signaling
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pathways in a cell or tissue. One such alternative for GSH drug delivery will be via
nanomedicine/liposome-encapsulated form.
7.4. N-isobutyrylcysteine (NIC)
One of the disadvantages of using NAC is its low bioavailability, due to its greater first pass
hydrolysis in biological systems. Therefore, a drug having similar effects as NAC but with
greater bioavailability might prove to be a more effective treatment for chronic bronchitis/
COPD. One such compound is NIC, which is also a thiol molecule with lesser first pass
hydrolysis and bioavailability as high as 80% compared to NAC [134]. However,
therapeutic evaluations of NIC against exacerbations in chronic bronchitis have revealed that
NIC did not do better than the placebo [129]. A similar non-effective result was reported in a
study in patients with COPD [134].
7.5. Erdosteine
Erdosteine is a thiol antioxidant having mucoactive properties (Fig 2), and the ability to
reduce bacterial adhesiveness. This compound was introduced as a mucolytic agent for the
treatment of chronic pulmonary diseases. Erdosteine breaks the disulfide bonds of mucus
glycoproteins, affecting the physical properties of the mucus, thus leading to increased
cough clearance [135]. In addition, erdosteine has been reported to have antioxidant, anti-
inflammatory, and antibacterial activity.
In a randomized, placebo-controlled clinical study, ‘Equalife’ involving oral administration
of 300 mg erdosteine twice daily for 8 months [121] showed significant reduction in
exacerbations compared to the placebo group. The same study also demonstrated that
patients receiving erdosteine showed significant improvements in their quality of health
without any adverse effect on lung function. In another clinical study involving
administration of erdosteine 300 mg twice a day for 7 – 10 days improved the symptoms and
reduced the length of time for the disease in patients with acute exacerbation of chronic
bronchitis and COPD [136]. Long-term treatment of stable COPD patients with erdosteine
reduced the rate of hospitalization and acute exacerbation. Furthermore, erdosteine has been
reported to impart health benefits in patients suffering from repeated, prolonged or severe
exacerbations of COPD [136–137]. Dal Negro et al. showed that erdosteine at a dose of 600
mg/day proved effective in significantly reducing ROS levels in peripheral blood of stable
COPD patients who are current smokers, together with reduction in levels of some
chemotactic proinflammatory cytokines (IL-6 and IL-8) in their bronchial secretions [138].
Recently, the anti-inflammatory properties of erdosteine were confirmed in a study
involving COPD subjects, wherein by its ability to reduce the proinflammatory eicosanoids
levels [139]. Hence, this compound may be a choice as another antioxidant and mucolytic
agent in management of COPD.
7.6. Carbocysteine
S-carboxymethylcysteine (carbocysteine or S-CMC) is a blocked thiol derivative of amino-
acid; L-cysteine (2). Oral preparations of carbocysteine both as S-CMC and its lysine salt
(S-CMC-lys) are available. The lysine salt is activated in the gastrointestinal tract post-
cleavage of the lysine residue to yield the active drug S-CMC. Carbocysteine is a muco-
active drug with reported in vitro free radical scavenging and anti-inflammatory properties.
While mucolytic drugs, such as NAC and erdosteine bear free sulphydryl (thiol) groups,
through which they split glycoprotein bonds in mucous, carbocysteine differs in structure
and mechanism of action from other commonly available mucolytics. The mucus produced
under the influence of carbocysteine, has increased sialomucin content. Sialomucins
influence the rheological properties of mucus via the inhibition of kinins, thereby reducing
or preventing bronchial inflammation and bronchospasm [140].
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In COPD patients treated with S-CMC-Lys for a 6-month period, Carpagnano et al
demonstrated a significant reduction in exhaled 8- isoprostane and pro-inflammatory
cytokine: IL-6, providing an in vivo support for the spate of in vitro evidences, proving that
the drug has anti-inflammatory and antioxidant properties [141]. Furthermore, anti-
inflammatory action of carbocysteine has been well documented in models of pulmonary
inflammation involving several different cytokine profiles and it has been shown to protect
against emphysema induced by cigarette smoke in rats [142]. In carrageenan-induced
pleurisy, oral administration of S-CMC-lys has been shown to attenuate neutrophil
recruitment in acute IL-1β-induced airway inflammation and neutrophil, macrophage and
eosinophil migration into the pleural space [143]. Carbocysteine attenuated mucus
glycoproteins hypersecretion and reduced inflammatory cells, free radical and elastase
activity in the bronchoalveolar lavage fluid of rats with sulfur dioxide-induced airway
inflammation have been reported [144].
Carbocysteine is shown to enhance both in vivo and in vitro muco-ciliary clearance velocity,
particularly in patients with chronic bronchitis with slow clearance before treatment [140].
Since carbocysteine has the potential to reduce bacterial respiratory tract infections in
COPD, it has been suggested that it may act through the inhibition of pathogen adherence to
cells. In vitro studies involving treatment with carbocysteine have demonstrated a significant
reduction in adherence of Moraxella catarrhalis (this bacteria causes exacerbations of
COPD) to the pharyngeal epithelial cells, of both healthy subjects and those with chronic
bronchitis, when compared to placebo treated group [145]. This observation has been further
corroborated by a similar observation that, carbocysteine significantly reduced attachment of
Streptococcus pneumoniae to pharyngeal epithelial cells taken from healthy subjects by
direct in vitro treatment of the cells with the drug [146]. Reduction in frequency of common
colds including infections and associated exacerbations in COPD patients on treatment with
carbocysteine have been attributed to its ability to decrease ICAM-1 expression in the
respiratory tract [147].
There are reports regarding the clinical use of carbocysteine to treat COPD patients with
mixed results on alterations in lung function and exacerbation rate (Table 3) [122, 147–155].
A recent study, particularly the PEACE study involving 709 Chinese COPD subjects, has
examined the effect of over three year period of treatment with carbocysteine (250 mg t.d.s)
focusing on the rate of COPD exacerbations. This study has revealed that COPD patients
whom were treated with carbocysteine experienced fewer numbers of exacerbations per year
[122]. Although very few side effects have been reported for carbocysteine, over-dosage
may cause mild side-effects, such as gastric discomfort. More systematic studies and
understanding the detailed mechanism of action of carbocysteine may uphold the
candidature of carbocysteine as a major therapeutic agent for treatment of respiratory
diseases including COPD. Furthermore, a longer use of carbocysteine may be more effective
for preventing acute exacerbations in patients with COPD. Overall, clinical studies have
revealed that carbocysteine is well-tolerated, has mucoactive properties (mucolytic) and can
also reduce bacterial adhesiveness. Currently, carbocysteine is considered to be a useful
muco-regulatory agent for the treatment of COPD that provides symptomatic relief to some
patients, along with resolute sputum production, and may reduce exacerbation rates.
Carbocystine may be choice as compared to NAC, or other available thiols in management
of COPD and its exacerbations.
7.7. Fudosteine
Fudosteine, [(−)-(R)-2-amino-3-(3-hydroxypropylthio)] propionic acid (Fig 2), has been
used in the treatment of chronic respiratory diseases, such as bronchial asthma, chronic
bronchitis, pulmonary emphysema, COPD, and bronchiectasis as a mucoactive agent [156–
157]. Fudosteine acts by increasing cysteine levels of the cells and has greater
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bioavailability than NAC. Fudosteine downregulates MUC5AC gene expression thus
inhibits mucin hypersecretion [156]. Although, little is known about its mode of action,
fudosteine has shown some promising potential in treatment of patients with COPD [158].
These findings suggest that fudosteine may be useful in controlling oxidative/carbonyl
stress-related mucus secretion states in patients with asthma, bronchiectasis or COPD.
Fudosteine (500 mg/kg, p.o.) significantly augmented the output volume of respiratory tract
fluid in rabbits and increased chloride ion concentration in bronchoalveolar lavage of rats
[159]. Fudosteine also reduced the activation of p38 MAPK and ERK pathways [156].
Fudosteine has also been shown to inhibit peroxynitrite-induced cellular alterations in lung
by direct scavenging of this free radical [160]. Further studies are required clinical efficacy
of fudosteine in treatment of COPD.
7.8. Ergothioneine
Ergothioneine (2-mercaptohistidine trimethylbetaine) is a naturally occurring antioxidant
found in most plants and animal tissues (Fig 2) [161]. Chemically, L-ergothioneine
corresponds to the betaine of 2-thio-L-histidine. In aqueous solution, the tautomeric-2-thio-
imidazole exists predominantly in the thione form. The compound is known to be formed
via hercynine from histidine, methionine, and cysteine in microorganisms. Ergothioneine
inhibits the peroxynitrite-dependent nitration of nitrotyrosine [162], and also inhibits
oxidative DNA repair and cell death [163]. Ergothioneine also inhibits the formation of
xanthine and hypoxanthine (a precursor of xanthine), which are shown to be activated in
patients with COPD [4–5]. The role of ergothioneine on S-nitrosoglutathione catabolism and
generation of vasodilatory NO has been shown [164].
Interestingly, ergothioneine increases cellular tolerance/availability of NAC. The role of
ergothioneine in inhibition of oxidative stress-mediated signal transduction mechanisms
involved in cellular inflammatory responses has been shown in lung epithelial cells.
Ergothioneine inhibits oxidative stress- and TNF-α-induced NF-κB activation and IL-8
release in alveolar epithelial cells [165]. Thus, ergothioneine may be a potential antioxidant/
anti-inflammatory agent to inhibit the chronic inflammatory response, which occurs in the
development of chronic inflammatory lung diseases including COPD. However, no
documented evidence are available to attest this in management of COPD.
8. Lipid peroxidation and protein carbonylation inhibitors/blockers
8.1. Edaravone (MC-186)
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a widely acclaimed and potent free-
radical scavenger and exhibits its antioxidant ability by inhibiting lipid peroxidation [166–
167]. Interestingly, edavarone can also inhibits protein carbonylation by direct carbonyl-
scavenging mechanism [168]. Protein carbonylation and carbonyl stress via aldehydes and
advanced glycation end-products occur in several pulmonary diseases including COPD and
hence it may be the direct of prevention strategies [2, 17, 169–170]. Since edaravone has
protective effects on both hemispheric embolization and transient cerebral ischemia, it has
therefore been clinically tested to treat acute brain infarction in Japan [171–173]. In a study
in rat model of ischemia/reperfusion injury, Ito et al. [174], has demonstrated that edaravone
ameliorated the lung injury induced by intestinal ischemia/reperfusion. In the same study
[174], edaravone was found to decrease infiltration of neutrophils, membrane lipid
peroxidation and downregulate expression of IL-6 mRNA in the lungs, leading to a
significant reduction in mortality. Edavarone also shown to be protective in acute
pancreatitis-associated lung injury by suppression of IL-6 and TNF-α [175]. Furthermore, it
has been shown that edaravone suppressed bleomycin-induced acute pulmonary injury in
rabbits [176] and paraquat-induced lung injury and fibrosis in rats [177], and suppresses
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fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis [178]. This
suggests an important role of edaravone in suppressing skin and lung fibrosis. The protective
effect of edaravone was demonstrated by its ability to inhibit lung injury and fibrosis via
decreasing lipid peroxidation and the enhancing prostaglandin E2 production in the
experimental murine system. Another analog MCI-186 (3-methyl-1-phenyl-pyrazolin-5-one)
is shown to have protective effects against free radical damage, but shown have biphasic
effects on deterioration of pulmonary fibrosis in mice [179]. Edaravone seems to be
interesting molecule which inhibits protein carbonylation, which occurs in response to
cigarette smoke and in patients with COPD. Hence, further studies are required to
demonstrate the therapeutic efficacy of edaravone in management of COPD and its
symptoms.
8.2. Lazaroids (U75412E or tirilazad mesylate): a nonglucocorticoid 21-aminosteroid
Lazaroids (21-aminsteroids, U75412E or trilizad mesylate) are a group of nonglucocorticoid
analogues of methyl-prednisolone which are able to penetrate hydrophobic regions of the
cell membrane, specifically to prevent peroxidation of membrane lipids [180–181]. The
protective efficacy of lazaroids has been reported in many animal models of lung injury,
such as injury by endotoxin [181], ischemic/reperfusion [182] and tobacco smoke [183]. The
findings from the above studies have revealed that lazaroids may exert their protective effect
by various mechanisms, inhibition of lipid peroxidation being the main. In a cigarette
smoke-induced lung injury model, it was found that aerosolized lazaroids could inhibit the
formation of free radicals and also inhibit release of TNF-α in alveolar macrophages [184–
185]. In another study, it was found that lazaroid U74389G was able to protect against
hyperoxia in rat type-II pneumocytes [186]. Lazaroid, U74006F was reported to protect
against endotoxin mediated lung injury in sheep and protected against antigen-induced
bronchoconstriction and bronchoalveolar eosinophilia in allergic sheep [187–188], and
sepsis-induced acute lung injury in minipigs [189]. Furthermore, lazaroids were found to
attenuate oxidant-induced lung injury by inhibiting the mRNA expression for E-selectin, P-
selectin, ICAM-1, and VCAM-1 [190]. However, studies are required to evaluate the
efficacy of lazaroids as therapeutic strategy in COPD, particularly in severe COPD where
steroid resistance occurs.
9. Conclusions
Oxidative stress is known to occur in the pathogenesis of COPD. Targeting oxidative stress
with pharmacological antioxidants or boosting the endogenous levels of antioxidants is
likely to be beneficial in the treatment and management of COPD. Several small molecule
antioxidant compounds have been investigated in clinical and pre-clinical trials.
Antioxidants, such as thiol molecules/donors, spin traps, antioxidant enzyme mimetics, and
inhibitors of oxidative stress and lipid peroxidation and protein carbonylation blockers have
potential to be used in treatment/management of COPD, as well as in different COPD
phenotypes. However, the clinical trials so far have been unsuccessful to clearly define (1)
the type of antioxidant, (2) regimen, and (3) time period of treatment in acute exacerbations
and pathogenesis of COPD. This is perhaps due to lack of understanding of the
pathophysiology of COPD and subtle differences in COPD phenotypes. It is, therefore,
important to identify the main source(s) of oxidant in a particular phenotype and accordingly
choose a particular antioxidant therapy or regimen for a given COPD phenotype.
Current therapy using antioxidants for COPD is symptomatic, e.g. thiol-based therapy is
mainly mucolytic (clearance of mucus, thereby minimizing the bacterial/viral load).
However, it is possible that antioxidant therapy becomes therapeutic based on future studies
involving novel compounds in amelioration of COPD. Furthermore, antioxidant compounds
may also enhance the efficacy of glucocorticoids by quenching oxidants and aldehydes in
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COPD patients. Although thiol antioxidant treatments have shown promising effects in
targeting ROS and oxidant-mediated cellular alterations, development of novel wide-
spectrum small molecule antioxidants with a good bioavailability and potency are needed in
clinical trials for COPD. Antioxidant therapy may affect important outcomes in COPD, such
as overcoming steroid resistance, mucus hypersecretion, inflammation and extracellular
matrix remodeling. Furthermore, the effects of a combination of various antioxidants along
with thiols, spin traps, lipid peroxidation/protein carbonylation inhibitors/blockers, or
enzyme mimetics is an interesting proposition worth investigating in patients with COPD.
Antioxidants (e.g. thiols and other molecules) may be combined with anti-inflammatories/
PDE4 inhibitor/Sirtuin1 activator, bronchodilators, steroids, antibiotics, and statins.
Furthermore, novel antioxidant strategies can be used as supplementing/pre-emptying agents
in management of COPD, as well as in susceptible smokers.
Highlights
Cigarette smoke causes oxidative stress in COPD.
Antioxidants are likely to have beneficial effects in management of COPD.
Thiols, enzyme mimetics, spin traps, and porphyrins are therapeutic agents.
Antioxidants have pharmacological effects in inhibiting cellular processes in COPD.
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Figure 1.
Chemical structures of thiol antioxidants
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Figure 2. Consequences of oxidative stress in pathogenesis of COPD
Inflammatory response is mediated by inhaled and/or cellular oxidants and carbonyls. These
oxidants activate alveolar macrophages, neutrophils, eosinophils, and epithelial cells,
leading to augmented endogenous ROS generation, redox imbalance, activation of redox-
sensitive transcription factors, mucus hypersecretion, extracellular matrix and small airway
remodeling. ROS can trigger several cellular and molecular events which are involved in
pathogenesis of COPD. These cellular and molecular events can be exploited as targets for
pharmacological antioxidant strategies in treatment of COPD.
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Table 1
Antioxidant therapeutic agents in COPD
Antioxidant compound
Thiol compounds N-acetyl-L-cysteine (NAC)
N-acystelyn (NAL)
N-isobutyrylcysteine (NIC)
Glutathione esters
S-carboxymethylcysteine (Carbocysteine)
Erdosteine
Fudosteine
Thioredoxin
Procysteine
Ergothioneine
Inducers of glutathione biosynthesis
Nrf2 activators CDDO-imidazolide
Sulforaphane
Chalcones (1,2-diphenyl-2-propen-1-ones)
Glutathione peroxidase and SODs
Mimetics Salen compounds
M40419, M 40403, and M40419
Manganese-metaloporphyrins, such as AEOL-10113 and AEOL-10150
Metaloporphyrins (MnTBAP)
MnTE-2-PyP
EUK compounds (EUK-189)
Ebselen
BXT-51072 (ALT-2074), and BXT-51077
Lipid peroxidation/protein carbonylation inhibitors/
blockers
Edaravone (MC-186)
Lazaroids/tirilazad (U75412E or tirilazad mesylate)
Other antioxidants/enzymes and oxidant scavengers Nitrone spin traps (NXY-059, STANZ)
Peroxynitrite decomposition catalysts
(FeTMPyP, FP15)
Porphyrins
Glutaredoxins
Peroxiredoxins
Polyphenols, natural products, and dietary agents Polyphenols/flavanoids/natural compounds (Curcumin, resveratrol, quercetin,
sulforaphane, lycopene, Acai, Apocynin, omega-3-fatty acid, Vitamin D)
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Table 2
Pros and cons of targeting oxidants with antioxidants in COPD
Antioxidant Pros Cons
Thiol compounds • Potent mucolytic
• Mild effects on exacerbation rates
• Lack of bioavailability
• Cause bronchoconstriction
• Form thiyl/cysteine radicals
Nrf2 activators • Protection seen in animal models
• Induce a variety of phase II genes/
enzymes
• Clinical studies are required
• Dramatically degraded in severe COPD
GOLD stages
• Carbonylation/oxidation of Nrf2/Keap1
• Prophylactic-potent inducer is needed
Targeting ROS using
SOD mimetics
• Protection seen in animal models
• Inhibit ECM remodeling
• Clinical studies are required
• May impair phagocytosis
• Alter endogenous redox homeostasis
Lipid peroxidation/
protein carbonylation
inhibitors/blockers
• Inhibit lipid peroxidation chain reactions
• Clinical studies are required
• Poor bioavailability
• Low presence at the site of microenvironment
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Table 3
Clinical trials conducted for the efficacy of thiol antioxidants in smokers and COPD
Clinical Trial Antioxidant Study Aim Outcome References
BRONCUS NAC Effect of NAC on FEV1 No effect. No change on decline
in FEV1 A reduction in lung
overinflation in patients with
severe COPD without inhaled
glucocorticoids. Decrease of
exacerbation if NAC and Inhaled
corticosteroids combined.
[110–111]
Systematic Cochrane
review of 23 randomized,
controlled trails
NAC (2 months of oral therapy) Effect of NAC and
antibiotics on number of
days of disability
No difference in lung function.
Significant reduction in days of
disability (0.65 day per patient
per month) and 29% reduction in
exacerbations
[112–113]
Systematic Cochrane
review of randomized,
controlled trials; 11 of 39
retrieved trials
NAC Use of validated score to
evaluate the quality of
each study
9 trials showed prevention of
exacerbation and 5 of which
addressed improvement of
symptoms compared with 34.6%
of patients receiving placebo
[114]
Meta-analysis of
published trials
NAC Assess possible
prophylactic benefits of
prolonged treatment
23% decrease in number of acute
exacerbations
[115]
- NAC (600 mg/d, 5 days and 600
mg, 3/d. 5days)
Effect of NAC on GSH
and cysteine
Increase of GSH at day 5 and
cysteine (plasma) at day 5
[116]
- NAC (600 mg once a day for 12
months)
Effect of NAC on H2O2
and TBARS in EBC
No change in TBARS levels
Reduce H2O2 levels
[117]
- NAC (600 mg/d, 7days) Effect of NAC on FEV1,
breathlessness
No difference compared to
placebo group
[118]
- NAC (600 mg/d) Effect of NAC on
cytokine and exhaled
breath condensate
(ECD)
Decrease IL-8 and ECP level in
NAC group
[119]
- NAC (600 mg x 2/d x 2 months) Effect of NAC on H2O2 Decrease H2O2 level in NAC
group
[120]
EQUALIFE studies Erdosteine-thiol compound,
300mg b.i.d for months
Effect on exacerbation
rate, hospitalization,
lung function and
quality of life
Decreased exacerbations and
fewer days in hospital. No loss
of lung function and
improvement in health-related
quality of life
[121]
- Erdosteine 300 mg twice a day
for 7 – 10 days
Effect on COPD
symptoms during
exacerbations and
hospitalization days
Improvement of symptoms and
reduced time of disease in
patients with acute exacerbation
of chronic bronchitis and COPD
[136–137]
Erdosteine 600 mg/day Effect on oxidative
stress and inflammation
Reduced ROS levels in
peripheral blood of stable COPD
patients who are current
smokers, together with reduction
in levels of IL-6 and IL-8 in
bronchial secretions
[138–139]
Small scale UK studies Carbocysteine Effect of 2.25–3.00 g
carbocysteine daily
along with placebo in
chronic bronchitis
Heterogeneous results on
alterations in FEV1 peak flow
rate and dyspnea scores
[148–151]
An Italian multi-center,
prospective, double-blind
RCT involving 662
outpatients with a
chronic bronchitis
Carbocysteine Effect of 2.7 g S-CMC-
Lys once daily for 6
months on COPD
patients
No significant difference in
baseline FEV1 between the
groups. Mean time to first
exacerbation was significantly
prolonged and significant
[152]
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Clinical Trial Antioxidant Study Aim Outcome References
reduction in mean days of acute
respiratory illness per patient.
A double–blind, parallel-
group study in the UK in
109 patients with chronic
bronchitis over 6 winter
months
Carbocysteine Effect of 750 mg
carbocysteine three
times daily compared
with placebo on peak
flow and exacerbation
rate.
No significant difference in
exacerbation rate. Significant
increases in peak flow from
baseline in both placebo and
intervention groups
[153]
RCTs in Tokyo in 156
patients with COPD over
a 12-month period
Carbocysteine Effect of 1.5 g
carbocysteine daily with
placebo
No significant differences in
severity of COPD. Significant
reduction in the number of
common colds and reduction in
rate of exacerbation
[154–155]
RCTs in Japan involving
142 patients with COPD
conducted over a 12-
month period
Carbocysteine Treatement with 500mg
carbocysteine three
times a day
Consistent reduction in
exacerbation frequency. No
change in lung function
[147]
PEACE study Carbocysteine (carbocisteine) Effect on rate of
exacerbations
Long-term (one year) use of
carbocysteine (1500 mg/day)
produced reduction in numbers
of exacerbations in patients with
COPD
[122]
BRONCUS = Bronchitis Randomized on N-acetyl-L-cysteine Cost Utility Study, bid= Twice daily; FEV1 = Forced expiratory volume in 1 second,
TBARS = Thiobarbituric acid reactive substances, NAC = N-acetyl-L-cysteine, EBC = Exhaled Breath Condensate, ECP: eosinophilic cationic
protein, RCT: Randomized placebo-controlled trials.
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